

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**INSIDE INFORMATION
REGISTRATION OF MEDIUM TERM NOTES BY THE
NATIONAL ASSOCIATION OF FINANCIAL MARKET
INSTITUTIONAL INVESTORS**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly owned subsidiary of the Company, has received a notice of acceptance of registration (Zhong Shi Xie Zhu [2026] No. MTN455) (the “**Notice**”) issued by the National Association of Financial Market Institutional Investors in relation to the proposed issuance of medium term notes by CR Pharmaceutical Holdings in the People’s Republic of China (the “**PRC**”). The Notice shall be effective for a period of two years from the issue date of the Notice, during which CR Pharmaceutical Commercial may issue medium term notes in an aggregate amount of RMB5 billion in tranches. If the proposed issuance of medium term notes proceeds, it is expected that the proceeds raised therefrom will mainly be used for replenishment of working capital, repayment of interest-bearing debts and other purposes in compliance with applicable laws and regulations.

The Company will make further announcement in relation to the proposed issuance of medium term notes as and when appropriate.

As the proposed issuance of the medium term notes may or may not proceed, shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 29 May 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.